Crizanlizumab is under clinical development by Novartis and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Crizanlizumab’s likelihood of approval (LoA) and phase transition for Myelofibrosis took place on 16 Nov 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

In addition, the same event on 16 Nov 2022 increased Crizanlizumab’s LoA and PTSR for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and increased LoA and PTSR for Post-Polycythemia Vera Myelofibrosis (PPV-MF).

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Crizanlizumab Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Crizanlizumab overview

Crizanlizumab-TMCA (Adakveo, Chylotrez) is a monoclonal antibody, produced by using recombinant DNA technology in chinese hamster ovary (CHO) cells. It is formulated as solution and concentrate solution for intravenous route of administration. Adakveo is indicated to reduce the frequency of vasoocclusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease.

Crizanlizumab (SEG101, SelG-1) is under development for the treatment of sickle cell disease, vaso-occlusive crisis associated with sickle cell disease. chronic kidney disease due to sickle cell nephropathy and primary myelofibrosis including post-essential thrombocythemia (ET) (PET-MF), post-polycythemia vera (PV) myelofibrosis (PPV-MF) and COVID-19 vasculopathy. The therapeutic candidate is administered as an intravenous infusion. It is a humanized monoclonal antibody that acts by targeting P-selectin.

Novartis overview

Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, immune disorders, and infections, among others. The company offers generic medicines and biosimilars through Sandoz. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.

Quick View Crizanlizumab LOA Data

Report Segments
  • Innovator (NME)
Drug Name
  • Crizanlizumab
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Genito Urinary System And Sex Hormones
  • Hematological Disorders
  • Infectious Disease
  • Oncology
Key Developers
  • Sponsor Company: Novartis
  • Originator: Oklahoma Medical Research Foundation
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.